JPS6233879B2 - - Google Patents

Info

Publication number
JPS6233879B2
JPS6233879B2 JP16732384A JP16732384A JPS6233879B2 JP S6233879 B2 JPS6233879 B2 JP S6233879B2 JP 16732384 A JP16732384 A JP 16732384A JP 16732384 A JP16732384 A JP 16732384A JP S6233879 B2 JPS6233879 B2 JP S6233879B2
Authority
JP
Japan
Prior art keywords
japanese encephalitis
encephalitis virus
gel
virus
cellulose sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP16732384A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6147185A (ja
Inventor
Kuniaki Sakamoto
Isao Goto
Tetsuo Kawahara
Mitsuo Sako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Original Assignee
KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO filed Critical KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Priority to JP59167323A priority Critical patent/JPS6147185A/ja
Priority to DE8585110011T priority patent/DE3578839D1/de
Priority to AT85110011T priority patent/ATE54938T1/de
Priority to CA000488282A priority patent/CA1251400A/en
Priority to EP19850110011 priority patent/EP0171765B1/en
Priority to KR1019850005759A priority patent/KR920009731B1/ko
Priority to US06/764,130 priority patent/US4725546A/en
Publication of JPS6147185A publication Critical patent/JPS6147185A/ja
Publication of JPS6233879B2 publication Critical patent/JPS6233879B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP59167323A 1984-08-09 1984-08-09 日本脳炎ウイルスの精製方法 Granted JPS6147185A (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP59167323A JPS6147185A (ja) 1984-08-09 1984-08-09 日本脳炎ウイルスの精製方法
DE8585110011T DE3578839D1 (de) 1984-08-09 1985-08-08 Verfahren zur reinigung des japanischen enzephalitisvirus.
AT85110011T ATE54938T1 (de) 1984-08-09 1985-08-08 Verfahren zur reinigung des japanischen enzephalitisvirus.
CA000488282A CA1251400A (en) 1984-08-09 1985-08-08 Method for purification of japanese encephalitis virus
EP19850110011 EP0171765B1 (en) 1984-08-09 1985-08-08 A method for purification of japanese encephalitis virus
KR1019850005759A KR920009731B1 (ko) 1984-08-09 1985-08-09 일본뇌염 바이러스의 정제방법
US06/764,130 US4725546A (en) 1984-08-09 1985-08-09 Method for purification of Japanese encephalitis virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59167323A JPS6147185A (ja) 1984-08-09 1984-08-09 日本脳炎ウイルスの精製方法

Publications (2)

Publication Number Publication Date
JPS6147185A JPS6147185A (ja) 1986-03-07
JPS6233879B2 true JPS6233879B2 (https=) 1987-07-23

Family

ID=15847614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59167323A Granted JPS6147185A (ja) 1984-08-09 1984-08-09 日本脳炎ウイルスの精製方法

Country Status (7)

Country Link
US (1) US4725546A (https=)
EP (1) EP0171765B1 (https=)
JP (1) JPS6147185A (https=)
KR (1) KR920009731B1 (https=)
AT (1) ATE54938T1 (https=)
CA (1) CA1251400A (https=)
DE (1) DE3578839D1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042737A1 (ja) 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
EP1662003A2 (en) 2000-11-08 2006-05-31 DNAVEC Research, Inc. Paramyxovirus vector for gene transfer to the cardiovascular system
WO2006134917A1 (ja) 2005-06-14 2006-12-21 Dnavec Corporation 抗体の作製方法
WO2007083644A1 (ja) 2006-01-17 2007-07-26 Dnavec Corporation 新規タンパク質発現系
WO2008007581A1 (en) 2006-07-13 2008-01-17 Dnavec Corporation Non-replicating paramyxoviridae virus vector
WO2008136438A1 (ja) 2007-04-27 2008-11-13 Kyushu University, National University Corporation 遺伝子治療用ウイルスベクター

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
US5447859A (en) * 1993-07-16 1995-09-05 Viagene Method for the purification or removal of retroviruses using sulfated cellulose
DE69515028T2 (de) * 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
CN1063970C (zh) * 1994-12-06 2001-04-04 卫生部北京生物制品研究所 用鳞翅目粘虫卵巢细胞制备流行性乙脑疫苗的方法及疫苗
FR2737412B1 (fr) * 1995-08-01 1997-10-24 Pasteur Merieux Serums Vacc Procede de production d'un vaccin contre le virus de l'encephalite japonaise et vaccin obtenu par ce procede
EP0841942B2 (fr) * 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
US6841374B1 (en) 1998-10-05 2005-01-11 Research Foundation For Microbial Diseases Of Osaka University Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
PL354822A1 (en) * 2002-06-30 2004-01-12 Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu Method of receiving purified bacteriophage preparations and new applications of polysaccharide or its esterificated derivative
JP2007523621A (ja) * 2003-06-18 2007-08-23 オニックス ファーマシューティカルズ，インコーポレイティド ウイルスを精製するための方法
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
DE102013017014B4 (de) 2013-10-14 2017-03-30 Sartorius Stedim Biotech Gmbh Sulfatierte Cellulosehydrat-Membran, Verfahren zur ihrer Herstellung und Verwendung der Membran als Adsorptionsmembran für die Virenaufreinigung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL131092C (https=) *
US3105012A (en) * 1961-10-19 1963-09-24 Parke Davis & Co Antigen products and means for producing the same
SE356735B (https=) * 1970-12-02 1973-06-04 Svenska Cellulosa Ab
JPS565204B2 (https=) * 1972-06-16 1981-02-04
US3842062A (en) * 1972-09-27 1974-10-15 Du Pont Water-soluble complexes of protein and anionic polyelectrolytes such as sodium carboxymethyl cellulose
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4160018A (en) * 1973-06-25 1979-07-03 Bjorklund Knut B Stabilized cancer associated polypeptide antigen and preparation thereof
IL49752A (en) * 1975-07-09 1979-07-25 Kabi Ab Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
JPS53133627A (en) * 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5879929A (ja) * 1981-11-05 1983-05-13 Biseibutsu Kagaku Kenkyusho:Kk 日本脳炎・豚パルポ混合ワクチン
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
US4515714A (en) * 1983-03-09 1985-05-07 Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute Method for purification of hepatitis B virus surface antigen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1662003A2 (en) 2000-11-08 2006-05-31 DNAVEC Research, Inc. Paramyxovirus vector for gene transfer to the cardiovascular system
WO2005042737A1 (ja) 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2006134917A1 (ja) 2005-06-14 2006-12-21 Dnavec Corporation 抗体の作製方法
WO2007083644A1 (ja) 2006-01-17 2007-07-26 Dnavec Corporation 新規タンパク質発現系
WO2008007581A1 (en) 2006-07-13 2008-01-17 Dnavec Corporation Non-replicating paramyxoviridae virus vector
WO2008136438A1 (ja) 2007-04-27 2008-11-13 Kyushu University, National University Corporation 遺伝子治療用ウイルスベクター

Also Published As

Publication number Publication date
KR920009731B1 (ko) 1992-10-22
ATE54938T1 (de) 1990-08-15
EP0171765B1 (en) 1990-07-25
JPS6147185A (ja) 1986-03-07
US4725546A (en) 1988-02-16
CA1251400A (en) 1989-03-21
EP0171765A3 (en) 1988-01-13
EP0171765A2 (en) 1986-02-19
DE3578839D1 (de) 1990-08-30
KR870001834A (ko) 1987-03-28

Similar Documents

Publication Publication Date Title
JPS6233879B2 (https=)
EP0171086B1 (en) A method for purification of influenza virus
US4725547A (en) Method for purfication of rabic virus
EP0011032B1 (en) Method for isolation of hbsag
KR890001927B1 (ko) 섬유질 헤마글루티닌의 정제방법
NO165478B (no) Fremgangsmaate for fremstilling av antigeniske preparater.
KR19990036028A (ko) 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
KR880002586B1 (ko) B형 간염 바이러스 표면 항원의 정제방법
DE69027013T2 (de) Verfahren zur Reinigung eines 69000 Dalton antigenischen Proteins aus Bordetella pertussis
Holland et al. ENTEROVIRAL RIBONUCLEIC ACID: II. Biological, Physical, and Chemical Studies
EP0175841B1 (en) Method for the production of pertussis component vaccine and combined vaccine of pertussis antigen; diphtheria toxoid and tetanus toxoid
CN115948351A (zh) 一种分离纯化cvb1的方法
CN111575249B (zh) 新型冠状病毒Vero细胞灭活疫苗病毒液的纯化方法
EP0298991B1 (en) Novel lectins derived from bacterial pili
Dowdle et al. Production and evaluation of a purified adenovirus group-specific (hexon) antigen for use in the diagnostic complement fixation test
EP0170162B1 (en) Method for the purification of leukocytosis-promoting factor haemagglutinin
JP2627186B2 (ja) レトロウイルスの精製方法
JPS6130528A (ja) Ｌｐｆ−ｈａの精製方法
Griffiths et al. The separation and purification of VI and O antigens of S. typhi using a column precipitation technique
CN114621963A (zh) 一种猪魏氏梭菌a型的亚单位疫苗及其制备
JPS641447B2 (https=)
JPS641446B2 (https=)
JPH0235726B2 (https=)
JPS641445B2 (https=)
JPS6241692B2 (https=)

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees